-
There are 12 self-paid medicines in the collection of 18 varieties!
Time of Update: 2022-08-15
. It is worth mentioning that both diosmin and compound α-ketoacid are clearly required for oral normal-release dosage forms in the bulk purchase of eight provinces and two districts, but the current problem is that these two varieties of tablets The medicine belongs to the national medical insurance, while the capsule belongs to the non-medical insurance .
-
Sihuan Pharmaceutical spins off "cash cow" generic drugs, why is the pain of generic innovation and upgrading?
Time of Update: 2022-08-15
Recently, Sihuan Pharmaceutical announced that it plans to sell some or all of the generic drugs and other non-core traditional medicine businesses and assets that have not met performance expectations or are not in line with the company's long-term strategic goals due to the impact of changes in the pharmaceutical industry and policies .
-
A large number of enterprises take the initiative to cancel the "Medical Device Registration Certificate"!
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On August 2, the State Food and Drug Administration announced that in accordance with the relevant provisions of the "Regulations on the Supervision and Administration of Medical Devices", according to the application of enterprises, the registration certificates of medical devices for 6 products are now cancelled .
-
Roche, Johnson & Johnson and many other multinational pharmaceutical companies announced their 2022 semi-annual financial reports. How about the "transcript"?
Time of Update: 2022-08-15
3%; consumption According to the sales data in the first half of the year, the revenue of the pharmaceutical business was US$26.
According to the data, Novartis’ net sales revenue in the first half of the year reached US$25.
-
Chain pharmacies are about to enter the "10,000-store era", and the "big eats" and "big eats" mergers and acquisitions are accelerating
Time of Update: 2022-08-15
have basically completed the online channel layout At present, leading chain pharmacies including Yixintang, Common People, Yifeng Pharmacy, Dashenlin, Jianzhijia, Shuyu Civilian, etc.
-
It is not easy for domestic new drugs to go overseas, this pharmaceutical company initiated another breakthrough!
Time of Update: 2022-08-15
It is not easy for domestic new drugs to go overseas In March this year, Innovent announced that the “going overseas” had failed, and the marketing application of its core product sintilimab was not approved by the US FDA .
-
The national centralized procurement has saved a total of 300 billion!
Time of Update: 2022-08-15
On July 22, the National Health and Health Commission held a press conference. The responsible comrades of the National Health and Health Commission, the National Development and Reform Commission, t
-
In the face of the retired tide lithium battery recycling online seminar, you can step on the "points"!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] Under the background of "dual carbon", the development of clean energy comes first and the energy storage industry develops later, both of which are insepara
-
Can cure the new crown?
Time of Update: 2022-08-15
Concept stocks soared, and many companies were busy clarifying What Tong Yigang did not expect was that this report also caused a skyrocketing rise in related traditional Chinese medicine stocks .
-
What are the key cases of the online seminar on heavy metal contaminated soil treatment?
Time of Update: 2022-08-15
, Ltd. Hao Jianqing, director of the Soil Remediation Office of the Ecological Environment Division, carried out the heavy metal pollution site treatment technology and engineering case sharing .
-
Innovative drug license out is getting better, another company sells overseas rights and interests of research products
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On July 28, CSPC announced that its subsidiary CSPC Jushi Bio has reached an agreement with Elevation Oncology, an American biopharmaceutical company, which obtained CSPC Jushi Bio-antibody-conjugated drug (ADC) SYSA1801 in Exclusive license agreement for development and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan) .
-
How do you see the pharmaceutical sector in the second quarter?
Time of Update: 2022-08-12
” Click to enter the exhibition pageIn the first quarter, the pharmaceutical sector experienced successive declines and new shares broke out .
” Click to enter the exhibition pageIn the first quarter, the pharmaceutical sector experienced successive declines and new shares broke out .
-
Shionogi over $480 million to help develop new antifungal drug
Time of Update: 2022-08-12
Recently, Shionogi and F2G announced a strategic collaboration to develop and commercialize olorofim, a novel antifungal drug for the treatment of invasive fungal infections, in Europe and Asia .
-
Innovative therapy dasiglucagon for congenital hyperinsulinemia reaches phase 3 clinical endpoint
Time of Update: 2022-08-12
Today, Zealand Pharma announced positive top-line results from a Phase 3 clinical trial of its glucagon analog dasiglucagon in pediatric patients with congenital hyperinsulinemia (CHI) .
html Today, Zealand Pharma announced positive top-line results from a Phase 3 clinical trial of its glucagon analog dasiglucagon in pediatric patients with congenital hyperinsulinemia (CHI) .
-
The "14th Five-Year" National Health Plan focuses on the high-quality development of traditional Chinese medicine
Time of Update: 2022-08-12
The "14th Five-Year" National Health Plan issued by the General Office of the State Council recently proposed to promote the inheritance, innovation and development of traditional Chinese medicine, g
-
50 million yuan invested in semiconductors!
Time of Update: 2022-08-12
Recently, Buchang Pharmaceutical announced that it plans to invest 50 million yuan to invest in Suzhou Yuanhepu Huazhixin Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Intelligent Fund") .
-
R&D investment of 12 pharmaceutical companies accounts for more than 10% of revenue
Time of Update: 2022-08-12
According to incomplete statistics in the industry, a total of 247 pharmaceutical companies in the two cities have invested more than 100 million yuan in R&D, including BeiGene, Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC, Innovent Bio, Junshi Bio, etc.
-
There are many variables in the cooperation of new drug research and development, and many pharmaceutical companies have terminated the cooperation agreement
Time of Update: 2022-08-12
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data released .
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data released .
-
Bian Que's medical book written by Sima Qian will be published to include 106 lost medical prescriptions
Time of Update: 2022-08-12
[Concurrent] Liu Changhua, Director of the Research Institute of Chinese Unearthed Medical Documents and Cultural Relics, Chengdu University of Traditional Chinese Medicine Because what (Tianhui Medical Slips) shows us is more traditional, older, and more primitive, such documents .
-
On May 20, a number of pharmaceutical companies were "confessed", and the net purchase amount of financing exceeded 100 million yuan
Time of Update: 2022-08-12
In addition to Shanghai Pharmaceuticals, the top pharmaceutical stocks in terms of financing net purchases on the day include Huahai Pharmaceutical, Junshi Bio and other stocks, with net purchases exceeding 100 million yuan.
